OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV

AIDS and Behavior

Volumn 16, Issue 8, 2012, Pages 2171-2180

  Nugent, Nicole R ^a,b,c   Lally, Michelle A ^c,d   Brown, Larry ^b,c   Knopik, Valerie S ^a,b,c   McGeary, John E ^a,c,e  

^a RHODE ISLAND HOSPITAL   (United States)

^b Bradley Hasbro Children's Research Center   (United States)

^c BROWN UNIVERSITY   (United States)

^d MIRIAM HOSPITAL   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Binge drinking; Gene; HIV; OPRM1; PTSD

Indexed keywords

MU OPIATE RECEPTOR; OPRM1 PROTEIN, HUMAN;

ADAPTIVE BEHAVIOR; ADULT; ALLELE; ARTICLE; BINGE DRINKING; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; MOTIVATION; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; SELF REPORT; SICKNESS IMPACT PROFILE; SOCIOECONOMICS;

ADAPTATION, PSYCHOLOGICAL; ADULT; ALLELES; BINGE DRINKING; GENOTYPE; HIV INFECTIONS; HUMANS; MIDDLE AGED; MOTIVATION; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, OPIOID, MU; SELF REPORT; SICKNESS IMPACT PROFILE; SOCIOECONOMIC FACTORS; STRESS DISORDERS, POST-TRAUMATIC; YOUNG ADULT;

EID: 84868573345     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-0095-8     Document Type: Article

References (83)

1. Kelly B, Raphael B, Judd F, Perdices M, Kernutt G, Burnett P, et al. Posttraumatic stress disorder in response to HIV infection. Gen Hosp Psychiatry. 1998;20(6):345-52.
2. Leserman J, Whetten K, Lowe K, Strangl D, Schwartz M, Thielman NM. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the South. Psychosom Med. 2005;67:500-7.
3. Safren SA, Gershuny BS, Hendriksen E. Symptoms of posttraumatic stress and death anxiety in persons with HIV and medication adherence difficulties. AIDS Patient Care STDS. 2003;17(12):657-64.
4. Katz S, Nevid JS. Risk factors associated with posttraumatic stress disorder symptomatology in HIV-infected women. AIDS Patient Care STDS. 2005;19(2):110-20.
5. Vranceanu AM, Safren SA, Lu M, Coady WM, Skolnik PR, Rogers WH, et al. The relationship of post-traumatic stress disorder and depression to antiretroviral medication adherence in persons with HIV. AIDS Patient Care STDS. 2008;22(4):313-21.
6. Martin L, Kagee A. Lifetime and HIV-related PTSD among persons recently diagnosed with HIV. AIDS Behav. 2011;15(1): 125-31.
7. Martinez A, Israelski D, Walker C, Koopman C. Posttraumatic stress disorder in women attending human immunodeficiency virus outpatient clinics. AIDS Patient Care STDS. 2002;16(6): 283-91.
8. Boarts J, Sledjeski E, Bogart L, Delahanty D. The differential impact of PTSD and depression on HIV disease markers and adherence to HAART in people living with HIV. AIDS Behav. 2006;10(3):253-61.
9. Cohen MA, Alfonso CA, Hoffman RG, Milau V, Carrera G. The impact of PTSD on treatment adherence in persons with HIV infection. Gen Hosp Psychiatry. 2001;23(5):294-6.
10. Delahanty DL, Bogart LM, Figler JL. Posttraumatic stress disorder symptoms, salivary cortisol, medication adherence, and CD4 levels in HIV-positive individuals. AIDS Care. 2004;16: 247-60.
11. Olley BO, Bolajoko AJ. Psychosocial determinants of HIVrelated quality of life among HIV-positive military in Nigeria. Int J STD AIDS. 2008;19(2):94-8.
12. Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis. 2006;194(9):690-6. doi:10.1097/01.nmd.0000235794.12794.8a.
13. Hien DA, Jiang H, Campbell ANC, Hu M-C, Miele GM, Cohen LR, et al. Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's clinical trials network. Am J Psychiatry. 2010;167(1):95-101.
14. Grayson CE, Nolen-Hoeksema S. Motives to drink as mediators between childhood sexual assault and alcohol problems in adult women. J Trauma Stress. 2005;18(2):137-45.
15. Ullman SE, Filipas HH, Townsend SM, Starzynski LL. Trauma exposure, posttraumatic stress disorder and problem drinking in sexual assault survivors. J Stud Alcohol. 2005;66:610-9.
16. Miranda R, Meyerson LA, Long PJ, Marx BP, Simpson SM. Sexual assault and alcohol use: exploring the self-medication hypothesis. Violence Vict. 2002;17:205-17.
17. Simpson TL. Childhood sexual abuse, PTS, and the functional roles of alcohol use among women drinkers. Subst Use Misuse. 2003;38(2):249-70.
18. Chander G, Himelhoch S, Moore R. Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs. 2006;66:769-89.
19. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the southeastern United States. J Acquir Immune Defic Syndr. 2006;42(3):298-306. doi:10.1097/01.qai.0000219773.82055.aa
20. Haller DL, Miles DR. Suicidal ideation among psychiatric patients with HIV: psychiatric morbidity and quality of life. AIDS Behav. 2003;7(2):101-8.
21. Merenlender-Wagner A, Dikshtein Y, Yadid G. The endorphin role in stress-related psychiatric disorders. Curr Drug Targets. 2009;10:1096-108.
22. Saxe G, Geary M, Bedard K, Bosquet M, Miller A, Koenen K, et al. Separation anxiety as a mediator between acute morphine administration and PTSD symptoms in injured children. Ann NY Acad Sci. 2006;1071:41-5.
23. Saxe G, Stoddard F, Courtney D, Cunningham K, Chawla N, Sheridan R, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry. 2001;40(8):915-21.
24. Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med. 2010;362(2):110-7.
25. Bryant RA, Creamer M, O'Donnell M, Silove D, McFarlane AC. A study of the protective function of acute morphine administration on subsequent posttraumatic stress disorder. Biol Psychiatry. 2009;65(5):438-40.
26. Morgan CA, Krystal JH, Southwick SM. Toward early pharmacological posttraumatic stress intervention. Biol Psychiatry. 2003;53(9):834-43.
27. McGaugh JL, Introini-Collison IB, Nagahara AH. Memoryenhancing effects of post-training naloxone: involvement of fl-noradrenergic influences in the amygdaloid complex. Brain Res. 1988;446(1):37-49.
28. Kreek MJ, Schlussman SD, Reed B, Zhang Y, Nielsen DA, Levran O, et al. Bidirectional translational research: progress in understanding addictive diseases. Neuropharmacology. 2009;56: 32-43.
29. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. Single-nucleotide polymorphism in the human Mu opioid receptor gene alters I○2-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95(16):9608-13.
30. Wand G, McCaul M, Gotjen D, Reynolds J, Lee S. Confirmation that offspring from families with alcohol-dependent individuals have greater hypothalamic-pituitary-adrenal axis activation induced by naloxone compared with offspring without a family history of alcohol dependence. Alcohol Clin Exp Res. 2001; 25(8):1134-9.
31. Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler H. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet. 2003; 118B(1):60-5.
32. Yehuda R, Golier J. Is there a rationale for cortisol-based treatments for PTSD? Expert Rev Neurother. 2009;9(8):1113-5.
33. Pitman RK, Delahanty DL. Conceptually driven pharmacologic approaches to acute trauma. CNS Spectr. 2005;10(2):99-106.
34. Delahanty DL, Nugent NR. Predicting PTSD prospectively based on prior trauma history, trauma severity, and immediate biologic responses. Ann NY Acad Sci. 2006;1071:27-40.
35. Amstadter AB, Nugent NR, Koenen KC. Genetics of PTSD: fear conditioning as a model for future research. Psychiatric Ann. 2009;39(6):358-67.
36. Pitman RK, van der Kolk BA, Orr SP, Greenberg MS. Naloxonereversible analgesic response to combat-related stimuli in posttraumatic stress disorder. a pilot study. Arch Gen Psychiatry. 1990;47(6):541-4.
37. van der Kolk BA, Greenberg MS, Orr SP, Pitman RK. Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmacol Bull. 1989;25(3):417-21.
38. Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr J Psychiatry Relat Sci. 1993;30(4):255-63.
39. Liberzon I, Taylor SF, Phan KL, Britton JC, Fig LM, Bueller JA, et al. Altered central mu-Opioid receptor binding after psychological trauma. Biol Psychiatry. 2007;61(9):1030-8.
40. van den Wildenberg E, Wiers RW, Dessers J, Janssen RGJH, Lambrichs EH, Smeets HJM, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res. 2007;31(1):1-10.
41. McGeary J, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30(8):1288-96.
42. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28(12):1789-95.
43. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a doubleblind placebo-controlled study. Arch Gen Psychiatry. 2007;64(9): 1069-77.
44. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of (micro)-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (combine) Study. Arch Gen Psychiatry. 2008;65(2):135-44.
45. Filbey F, Ray L, Smolen A, Claus E, Audette A, Hutchinson KE. Differential neural response to alcohol proming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res. 2008;32(7):1113-23.
46. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2010;16(18):809-17.
47. Wiers R, Rinck M, Dictus M, van den Wildenberg E. Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. Genes Brain Behav. 2009;8(1):101-6.
48. Ray LA. Stress-induced and cue-induced craving for alcohol in heavy drinkers: preliminary evidence of genetic moderation by the OPRM1 and CRH-BP genes. Alcohol Clin Exp Res. 2010; 35(1):166-74.
49. Max M, Wu T, Atlas S, Edwards R, Haythornthwaite J, Bollettino A, et al. A clinical genetic method to identify mechanisms by which pain causes depression and anxiety. Mol Pain. 2006;2(1):14
50. Matsunaga M, Isowa T, Murakami H, Kasugai K, Yoneda M, Kaneko H, et al. Association of polymorphism in the human (mu)-opioid receptor OPRM1 gene with proinflammatory cytokine levels and health perception. Brain Behav Immu. 2009; 23(7):931-5.
51. Norman SB, Stein MB, Davidson JRT. Profiling posttraumatic functional impairment. J Nerv Ment Dis. 2007;195(1):48-53. doi: 10.1097/01.nmd.0000252135. 25114.02
52. Marshall RD, Olfson M, Hellman F, Blanco C, Guardino M, Struening EL. Comorbidity, impairment, and suicidality in subthreshold PTSD. Am J Psychiatry. 2001;158:1467-73.
53. Grubaugh AL, Magruder KM, Waldrop AE, Elhai JD, Knapp RG, Frueh BC. Subthreshold PTSD in primary care: prevalence, psychiatric disorders, healthcare use, and functional status. J Nerv Ment Dis. 2005;193(10):658-64.
54. Breslau N, Lucia VC, Davis GC. Partial PTSD versus full PTSD: an empirical examination of associated impairment. Psychol Med. 2004;34(07):1205-14.
55. Corapioglu A, Tural U, et al. Subthreshold post traumatic stress disorder in the survivors of Marmara earthquake. Primary Care Psychiatry. 2004;9(4):137-44.
56. Cukor J, Wyka K, Jayasinghe N, Difede J. The nature and course of subthreshold PTSD. J Anxiety Disord. 2010;24(8):918-23.
57. Galai N, Strathdee SA, Vlahov D, Bareta J, Macalino G, Celentano DD. ACASI versus interview administered questionnaires for sensitive risk behaviors: Results of a cross-over randomized trial among injection drug users. International Conference on AIDS. 2004;15:11-6.
58. Waruru AK, Nduati R, Tylleskar T. Audio computer-assisted self-interviewing (ACASI) may avert socially desirable responses about infant feeding in the context of HIV. BMC Med Inform Decis Mak. 2005;5(24):1-7.
59. Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB. The reach (reaching for excellence in adolescent care and health) project: study design, methods, and population profile. J Adolesc Health. 2001;29(3):8-18.
60. Saunders JB, Aasland O, Babor T, de la Fuente JR, Grant M. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction. 1993;88:791-804.
61. Babor TF, de la Fuente JR, Saunders J, Grant M, editors. AUDIT: the alcohol use disorders identification test: guidelines for use in primary health care, revision, WHO document No. WHO/PSA/92.4. Geneva: World Health Organization; 1992.
62. Weiss D, Marmar CR, editors. The impact of event scale - revised. New York: Guilford; 1997.
63. Cooper ML, Russell M, Skinner JB, Windle M. Development and validation of a three-dimensional measure of drinking motives. Psychol Assess. 1992;4:123-32.
64. Muthen LK, Muthen BO. Mplus Version 3.11. Los Angeles: Muthen & Muthen; 2004.
65. Freeman B, Powell J, Ball D, Hill L, Craig I, Plomin R. DNA by mail: an inexpensive and noninvasive method for collecting DNA samples from widely dispersed populations. Behav Genet. 1997;27(3):251-7.
66. Lench N, Stainer P, Williamson R. Simple noninvasive method to obtain DNA for gene analysis. Lancet. 1988;1(8599):1356-8.
67. Meulenbelt I, Droog S, Trommelen GJ, et al. High-yield noninvasive human genomic DNA isolation method for genetic studies in geographically dispersed families and populations. Am J Hum Genet. 1995;57:1252-4.
68. Spitz E, Moutier R, Reed T, et al. Comparative diagnoses of twin zygosity by SSLP variant analysis, questionnaires, and dermatoglyphic analysis. Behav Genet. 1996;26:55-63.
69. O'Cleirigh C, Ironson G, Smits JAJ. Does distress tolerance moderate the impact of major life events on psychosocial variables and behaviors important in the management of HIV? Behav Ther. 2007;38(3):314-23.
70. Ironson G, O'Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, et al. Psychosocial factors predict CD4 and viral load change in men and women with HIV in the era of HAART. Psychosom Med. 2005;67:1013-21.
71. Creamer M, Bell R, Failla S. Psychometric properties of the impact of event scale-revised. Behav Res Ther. 2003;41:1489-96.
72. Asukai N, Kato H, Kawamura N, Kim YH, Yamamoto K, Kishimoto J, et al. Reliability and validity of the Japanese language version of the impact of event scale-revised (Ies-R-J): four studies of different traumatic events. J Nerv Ment Dis. 2002;190(3):175-82.
73. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the (mu)-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83(3):262-8.
74. Dixon LJ, Leen-Feldner EW, Ham LS, Feldner MT, Lewis SF. Alcohol use motives among traumatic event-exposed, treatmentseeking adolescents: associations with posttraumatic stress. Addict Behav. 2009;34(12):1065-8.
75. Gu C, Li P, Hu B, Ouyang X, Fu J, Gao J, et al. Chronic morphine selectively impairs cued fear extinction in rats: implications for anxiety disorders associated with opiate use. Neuropsychopharmacology. 2007;33(3):666-73.
76. Ho W-Z, Guo C-J, Yuan C-S, Douglas SD, Moss J. Methylnaltrexone antagonizes opioid-mediated enhancement of HIV infection of human blood mononuclear phagocytes. J Pharmacol Exp Ther. 2003;307(3):1158-62.
77. Steele AD, Henderson EE, Rogers TJ. Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology. 2003;309(1):99-107.
78. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther. 2004;11(5):354-65.
79. Delahanty DL, Nugent NR, Christopher NC, Walsh M. Initial urinary epinephrine and cortisol levels predict acute PTSD symptoms in child trauma victims. Psychoneuroendocrinology. 2005;30(2):121-8.
80. Delahanty DL, Raimonde AJ, Spoonster E. Initial posttraumatic urinary cortisol levels predict subsequent PTSD symptoms in motor vehicle accidents. Biol Psychiatry. 2000;48(9):940-7.
81. Amstadter A, Nugent NR, Yang BZ, Saxe G, Smoller J, Moorjan P, Haddad S, Basu A, Siburian R, Fagerness J, Koenen K. Corticotropin Releasing Hormone gene (CRHR1) and PTSD in pediatric injury patients. Special Issue of Disease Markers: Molecular Biology of PTSD. 2011;30(2-3):89-99.
82. Hernandez-Avila C, Covault J, Wand G, Zhang H, Gelernter J, Kranzler H. Population-specific effects of the Asn40Asp polymorphism at the mu-opioid gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics. 2007;17(12):1031-8.
83. van der Zwaluw CS, van den Wildenberg E, Wiers RW, Franke B, Buitelaar J, Scholte RHJ, et al. Polymorphisms in the mu-opioid receptor gene (OPRM1) and the implications for alcohol dependence in humans. Pharmacogenomics. 2007;8(10):1427-36.